Computed tomography screening for lung cancer
- PMID: 23512063
- DOI: 10.1001/jama.2012.216988
Computed tomography screening for lung cancer
Abstract
Importance: Low-dose computed tomography (CT) screening was shown to reduce lung cancer-specific mortality in a large randomized trial of a high-risk population. The decision to pursue CT screening for lung cancer is a timely question raised by individuals at risk of lung cancer and by their health care practitioners.
Objectives: To discuss the evidence for use of chest x-rays and low-dose CT in screening for lung cancer; to describe potential benefits, harms, and uncertainties of CT screening; and to review current guidelines for CT screening.
Evidence review: MEDLINE and the Cochrane Library were searched from 1984 to 2012. Additional citations were obtained from lists of references from select research and review articles on this topic. Evidence was graded using the American Hospital Association level of evidence guidelines.
Findings: Low-dose CT screening has been associated with a 20% reduction in lung cancer mortality in a large randomized controlled trial (National Lung Screening Trial [NLST]) of a high-risk population. Mortality data have not yet been reported for 5 other randomized controlled trials, and the sample sizes were too small to detect a meaningful difference in 2 other completed trials. A major risk of CT screening is a high false-positive rate, with associated risks and costs associated with follow-up CT scans and the potential for more invasive diagnostic procedures. Published guidelines for screening indicate a consensus that screening may be indicated for individuals who meet entry criteria for the NLST, but some guidelines expand their recommendations for screening beyond these criteria.
Conclusions and relevance: Individuals at high risk of lung cancer who meet the criteria for CT screening in published guidelines should participate in an informed and shared decision-making process by discussing the potential benefits, harms, and uncertainties of screening with their physicians.
Similar articles
-
Screening for lung cancer. Too many uncertainties, even for smokers.Prescrire Int. 2014 Jan;23(145):19-23. Prescrire Int. 2014. PMID: 24516909 Review.
-
Lung cancer screening: the radiologist's perspective.Semin Respir Crit Care Med. 2014 Feb;35(1):91-8. doi: 10.1055/s-0033-1363455. Epub 2014 Jan 30. Semin Respir Crit Care Med. 2014. PMID: 24481763 Review.
-
Screening for lung cancer.Cochrane Database Syst Rev. 2013 Jun 21;2013(6):CD001991. doi: 10.1002/14651858.CD001991.pub3. Cochrane Database Syst Rev. 2013. PMID: 23794187 Free PMC article. Review.
-
Cumulative incidence of false-positive test results in lung cancer screening: a randomized trial.Ann Intern Med. 2010 Apr 20;152(8):505-12, W176-80. doi: 10.7326/0003-4819-152-8-201004200-00007. Ann Intern Med. 2010. PMID: 20404381 Clinical Trial.
-
False-positive screens and lung cancer risk in the National Lung Screening Trial: Implications for shared decision-making.J Med Screen. 2018 Jun;25(2):110-112. doi: 10.1177/0969141317727771. Epub 2017 Sep 20. J Med Screen. 2018. PMID: 28929865 Clinical Trial.
Cited by
-
Artificial intelligence methods available for cancer research.Front Med. 2024 Oct;18(5):778-797. doi: 10.1007/s11684-024-1085-3. Epub 2024 Aug 8. Front Med. 2024. PMID: 39115792 Review.
-
Plasma exosomal miR-1290 and miR-29c-3p as diagnostic biomarkers for lung cancer.Heliyon. 2023 Oct 17;9(10):e21059. doi: 10.1016/j.heliyon.2023.e21059. eCollection 2023 Oct. Heliyon. 2023. PMID: 37916122 Free PMC article.
-
Early detection of lung cancer in a real-world cohort via tumor-associated immune autoantibody and imaging combination.Front Oncol. 2023 Apr 4;13:1166894. doi: 10.3389/fonc.2023.1166894. eCollection 2023. Front Oncol. 2023. PMID: 37081975 Free PMC article.
-
The combination of a seven-autoantibody panel with computed tomography scanning can enhance the diagnostic efficiency of non-small cell lung cancer.Front Oncol. 2022 Nov 30;12:1047019. doi: 10.3389/fonc.2022.1047019. eCollection 2022. Front Oncol. 2022. PMID: 36531072 Free PMC article.
-
Improving the efficiency of identifying malignant pulmonary nodules before surgery via a combination of artificial intelligence CT image recognition and serum autoantibodies.Eur Radiol. 2023 May;33(5):3092-3102. doi: 10.1007/s00330-022-09317-x. Epub 2022 Dec 8. Eur Radiol. 2023. PMID: 36480027 Clinical Trial.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
